Immunoglobulin G1, anti-(human neuregulin receptor HER3) (human monoclonal U3-1287 heavy chain), disulfide with human monoclonal U3-1287 κ-chain, dimer
Immunoglobulin G1, anti-(human neuregulin receptor HER3) (human monoclonal U3-1287 heavy chain), disulfide with human monoclonal U3-1287 κ-chain, dimer Basic information
- Product Name:
- Immunoglobulin G1, anti-(human neuregulin receptor HER3) (human monoclonal U3-1287 heavy chain), disulfide with human monoclonal U3-1287 κ-chain, dimer
- Synonyms:
-
- Immunoglobulin G1, anti-(human neuregulin receptor HER3) (human monoclonal U3-1287 heavy chain), disulfide with human monoclonal U3-1287 κ-chain, dimer
- Patritumab
- Research Grade Patritumab (DHD48404)
- Patritumab (anti-ERBB3)
- U3-1287|||AMG-888
- Research Grade Patritumab
- CAS:
- 1262787-83-6
- MW:
- 0
- Mol File:
- Mol File
Immunoglobulin G1, anti-(human neuregulin receptor HER3) (human monoclonal U3-1287 heavy chain), disulfide with human monoclonal U3-1287 κ-chain, dimer Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Immunoglobulin G1, anti-(human neuregulin receptor HER3) (human monoclonal U3-1287 heavy chain), disulfide with human monoclonal U3-1287 κ-chain, dimer Usage And Synthesis
Uses
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab.html" class="link-product" target="_blank">Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors[1].
in vivo
Patritumab (1 mg/mouse; i.p.; twice a week for 4 weeks) combines with 1 mg Cetuximab and restores Cetuximab sensitivity in DiFi-HRG tumor xenografts model in mice[1].
Heregulin produced by colorectal cancer tumors harboring wild-type KRAS induces Cetuximab resistance, and that combination therapy with cetuximab and patritumab overcomes such resistance in vivo[1].
| Animal Model: | Female athymic nude mice (BALB/c; 5-6 weeks old) with DiFi-Mock1 or DiFi-HRG4 (s.c.)[1] |
| Dosage: | 1 mg/body |
| Administration: | Intraperitoneal injection; twice a week for 4 weeks |
| Result: | Individual Patritumab treatment had little effect on the growth of tumors formed by either cell line. Combination of Cetuximab and Patritumab induced substantial regression of DiFi-HRG4 xenografts. |
References
[1] Kawakami H, et al. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. Oncotarget. 2014 Dec 15;5(23):11847-56. DOI:10.18632/oncotarget.2663
Immunoglobulin G1, anti-(human neuregulin receptor HER3) (human monoclonal U3-1287 heavy chain), disulfide with human monoclonal U3-1287 κ-chain, dimerSupplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 177-54423994 17754423994
- 2853530910@QQ.com
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Tel
- 15817493340
- 981810490@qq.com
- Tel
- 027-65317797 15926423062
- 422450190@qq.com